Comparative Pharmacology
Head-to-head clinical analysis: M V I 12 LYOPHILIZED versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V I 12 LYOPHILIZED versus MVC PLUS.
M.V.I.-12 LYOPHILIZED vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential vitamins for normal metabolic function, acting as cofactors in enzymatic reactions, including energy production, red blood cell synthesis, and antioxidant defense.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
10 mL (one vial) intravenously once daily, infused over at least 30 minutes.
10 mg orally once daily.
None Documented
None Documented
Variable by vitamin: thiamine ~24h, riboflavin ~18h, pyridoxine ~30h, cyanocobalamin ~6 days, ascorbic acid ~8h, retinol ~20h, ergocalciferol ~19 days, alpha-tocopherol ~10h, phytonadione ~4h. Clinical context: short t1/2 of water-soluble vitamins requires daily dosing; long t1/2 of fat-soluble vitamins allows less frequent dosing but risk of accumulation.
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Renal: water-soluble vitamins (B-complex, C) are excreted primarily via kidneys, with excess eliminated unchanged. Fat-soluble vitamins (A, D, E, K) are eliminated via bile and feces; renal excretion is minimal. Specific percentages: thiamine 80-90% renal, riboflavin 60-70% renal, pyridoxine 70-80% renal, cyanocobalamin 50-60% renal, ascorbic acid 60-70% renal; fat-soluble vitamins >90% biliary/fecal.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Multivitamin
Multivitamin/Mineral Supplement